BOYEN THERAPEUTICS, INC.
Area: Pharmaceutical and Medical Devices
Booth No: M425
Website: http://www.boyentherapeutics.com/
Exhibitor Profile
BoYen has a platform that creates patentable new drug candidates. Currently, 3 candidates are under development. BY-101 is an USFDA designated orphan drug with a 7-year marketing exclusivity; the phase 2 candidate is intended for the treatment of acute myeloid leukemia (AML). BY-102 is a patented drug candidate for the treatment of multiple sclerosis and other immune related diseases. Its phase 1 trial begins this fall. BY-103 is a patented drug candidate for oral combination treatment of AML.
Brands
BoYen Therapeutics
Exhibitors you may be interested in
Highest Rated